NAT10 and neoplasm: Furthermore, NAT10 knockdown profoundly improved the efficacy of PD‐L1 blockade therapy by impairing tumor cell glycolysis, reducing lactic acid production, and enhancing immunosurveillance within the TME, ultimately resulting in tumor regression.